GlassScriptPhysician profile
Suzan Hadwan
NPI 1962857607
$6,026.77
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $539 · 2021: $1,524 · 2022: $2,545 · 2023: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $736.51 | 2020-2023 | |
| Biogen, INC. | $723.00 | 2020-2023 | Vumerity, Tysabri |
| Emd Serono, INC. | $667.59 | 2020-2023 | Mavenclad |
| Genzyme Corporation | $432.30 | 2019-2022 | |
| Horizon Therapeutics Plc | $359.47 | 2022 | |
| Amgen INC. | $320.70 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $275.08 | 2019-2022 | |
| Genentech USA, INC. | $238.68 | 2019-2022 | |
| Lundbeck LLC | $209.56 | 2021-2022 | |
| Allergan, INC. | $207.13 | 2020-2022 | |
| Abbvie INC. | $192.55 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $174.27 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $172.66 | 2019-2023 | Ajovy |
| Alnylam Pharmaceuticals INC. | $155.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $147.43 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $137.77 | 2020-2022 | |
| Lilly USA, LLC | $118.41 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $113.74 | 2022 | |
| Greenwich Biosciences, INC. | $96.21 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $95.75 | 2021-2022 | |
| Medtronic, INC. | $77.95 | 2021-2022 | |
| Octapharma USA, INC. | $58.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.80 | 2022 | |
| Medtronic Vascular, INC. | $35.68 | 2020 | |
| Sunovion Pharmaceuticals INC. | $25.87 | 2022 | |
| Aquestive Therapeutics, INC. | $24.84 | 2020 | |
| Ani Pharmaceuticals, INC. | $23.50 | 2023 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $23.02 | 2020 | |
| Janssen Pharmaceuticals, INC | $22.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.52 | 2021 | |
| Merz Pharmaceuticals, LLC | $18.06 | 2021 | |
| Otto Bock Healthcare LP | $17.96 | 2021 | |
| Neurelis, INC. | $15.18 | 2020 | |
| Banner Life Sciences, LLC | $14.84 | 2021 | |
| Acorda Therapeutics, INC | $14.10 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzan Hadwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.